Predictive model for sarcopenia in patients with non-small cell lung cancer and malignant pleural effusion

被引:0
|
作者
Gao, Hengxing [1 ,2 ]
Zou, Xuexue [3 ]
Fan, Meng [1 ]
Chen, Mingwei [1 ]
机构
[1] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Resp & Crit Care Med, 277 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Affiliated Hosp 1, Medx Inst, Xian 710061, Shaanxi, Peoples R China
[3] Binzhou Med Univ Hosp, Dept Radiol, 661 Yellow River Rd, Binzhou 256600, Shandong, Peoples R China
关键词
Sarcopenia; Non-small cell lung cancer; Malignant pleural effusion; Predictive indicators; Nomogram; OUTCOMES; RISK;
D O I
10.1186/s12885-025-13772-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundSarcopenia in patients with non-small cell lung cancer (NSCLC) is often indicative of a more aggressive disease course and a poorer prognosis. Nevertheless, there have been limited studies that specifically examined clinical parameters to predict sarcopenia in individuals with malignant pleural effusion (MPE). Our objective is to investigate the potential correlations between commonly utilized clinical variables and reduced muscle mass in NSCLC patients who also have MPE.MethodsThis retrospective study examined the clinicopathological data and imaging characteristics of NSCLC patients admitted to the hospital with MPE. The Least Absolute Shrinkage and Selection Operator (LASSO) algorithm was employed to select the most appropriate variables for model creation, effectively reducing the chance of overfitting. Logistic regression analysis was conducted to pinpoint the independent factors predicting sarcopenia in NSCLC patients with MPE. Subsequently, a nomogram was formulated to estimate the sarcopenia risk for individual patient. The efficacy of this nomogram was assessed through various metrics, including the receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).ResultsA total of 139 patients, with an average age of 66 years and a majority being male (56.8%), were included in this study. Multivariate logistic regression analysis revealed that age, body mass index (BMI), albumin (Alb), and cytokeratin-19-fragment (CY21-1) were all independent predictors of sarcopenia in NSCLC patients with MPE. A nomogram was developed to facilitate personalized prediction of sarcopenia for individual patient. The ROC curve demonstrated that the nomogram model incorporating these predictive factors achieved an area under the curve (AUC) of 0.889, indicating its discriminatory power in predicting sarcopenia. The calibration curve demonstrated a strong concordance between the actual and the anticipated sarcopenia risk. DCA further confirmed that the nomogram showed good clinical applicability and net benefits in sarcopenia prediction.ConclusionsCertain commonly used clinical characteristics were found to be associated with decreased skeletal muscle mass. Specifically, age, BMI, Alb, and CY21-1 levels emerged as predictive indicators for sarcopenia among NSCLC patients with MPE. These indicators have the potential to serve as effective alternatives to traditional computed tomography (CT) evaluation in assessing sarcopenia.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Role of molecular testing for malignant pleural effusion in targeted therapy for advanced non-small cell lung cancer
    Lin, Rixu
    Li, Yida
    Lin, Yi
    Tian, Wenyi
    Jiang, Lei
    Li, Jianmin
    DIAGNOSTIC CYTOPATHOLOGY, 2023, 51 (07) : 397 - 405
  • [42] Research progress of antiangiogenic therapy and immunotherapy in malignant pleural effusion associated with non-small cell lung cancer
    Gu, Yan
    Jia, Junbin
    RESPIROLOGY, 2023, 28 : 276 - 276
  • [43] Clinical and Molecular Features of Malignant Pleural Effusion in Non-Small Cell Lung Cancer (NSCLC) of a Caucasian Population
    Lojo-Rodriguez, Irene
    Botana-Rial, Maribel
    Gonzalez-Montaos, Almudena
    Leiro-Fernandez, Virginia
    Gonzalez-Pineiro, Ana
    Ramos-Hernandez, Cristina
    Fernandez-Villar, Alberto
    MEDICINA-LITHUANIA, 2024, 60 (11):
  • [44] Malignant pleural effusion in non-small cell hung cancer - Time for a stage revision?
    Mott, FE
    Sharma, N
    Ashley, P
    CHEST, 2001, 119 (01) : 317 - 318
  • [45] Sarcopenia as a Predictive Factor for Carboplatin Toxicity in Patients with Advanced Non-Small Cell Lung Cancer
    Turcott, Jenny G.
    Miyagui, Sayako M.
    Torres, Salvador Gutierrez
    Cardenas-Fernandez, Daniela
    Caballe-Perez, Enrique
    Rios-Garcia, Eduardo
    Cardona, Andres F.
    Rolfo, Christian
    Arrieta, Oscar
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2024, 76 (10): : 985 - 993
  • [46] Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer
    Turcott, J.
    Miyagui, S. M.
    Caballe-Perez, E.
    Gutierrez Torres, S. Salvador
    Daniela Cardenas-Fernandez, D.
    Eduardo Rios-Garcia, E.
    Cardona, A. F.
    Rolfo, C. Christian
    Arrieta, O.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S607 - S608
  • [47] Effect of percutaneous radiofrequency ablation after thoracoscopic pleurodesis for treating non-small cell lung cancer patients with malignant pleural effusion and/or pleural dissemination
    Liu, Baodong
    Liu, Lei
    Hu, Mu
    Qian, Kun
    Li, Yuanbo
    THORACIC CANCER, 2016, 7 (05) : 549 - 555
  • [49] Pleural effusion and pulmonary injury as an unusual complication to chemotherapy in non-small cell lung cancer patients
    Stathopoulos, GP
    Dourakis, SP
    Perdicaris, G
    Promponas, IE
    ONCOLOGY REPORTS, 2000, 7 (06) : 1311 - 1315
  • [50] Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer
    Kasahara, K
    Shibata, K
    Shintano, H
    Iwasa, KI
    Sone, T
    Kimura, H
    Nobata, K
    Hirose, T
    Yoshimi, Y
    Katayama, N
    Ishiura, Y
    Kita, T
    Nishi, K
    Nakatsumi, Y
    Ryoma, Y
    Fujimura, M
    Nakao, S
    ANTICANCER RESEARCH, 2006, 26 (2B) : 1495 - 1499